Biota signs new flu diagnostic agreement
Wednesday, 24 March, 2004
Biota (ASX:BTA) has signed a new agreement with its US-based flu diagnostics partner Thermo Electron giving it a profit share in a second influenza diagnostic kit, FLU OIA A/B.
The new agreement is similar to a previous profit share arrangement with Thermo for the FLU OIA test, which brought AUD$2.3 million of revenues into the company in the first half of this financial year.
CEO Peter Molloy said a US$750,000 payment to Thermo to contribute towards product development costs would be fully offset by expected revenues from the new product during the second half of the current financial year, and the company expects to see significant revenues from the two tests over the next few years.
The two companies hope to expand the market for flu diagnostics. Outside the US, Thermo has exclusive marketing rights for both products in Europe, Japan and Australia/New Zealand, while Biota's territory includes Asia and the rest of the world.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
